

Bimizza®

(150 mcg desogestrol +
20 mcg ethinylestradiol)

Oral contraceptive pill

Take
Bimizza®
with
confidence



About your pack of Bimizza®

Each pack of Bimizza® contains 63 tablets presented in 3 x 21 blister pack strips, which is sufficient for 3 separate 28 day cycles of contraceptive cover.

Each box of Bimizza® also contains a detailed **Patient Information Leaflet**, which you should read carefully and put in a safe place. This provides important information that you should know when taking Bimizza®, such as guidance on:

- What to do if you miss a pill or several pills
- What to do if you are late taking your pill
- Medicines or illnesses that could make your pill less effective
- Potential side effects, and what to do if they occur
- Warning signs that indicate you should stop taking Bimizza® and consult your doctor

You can also find out about Bimizza® at: www.morningsidecontraceptives.com. Simply go the website and click on 'I have been prescribed a Morningside Contraceptive' then select 'view more' under Bimizza®.

About your Bimizza® prescription

Your doctor or other healthcare provider has prescribed Bimizza® as your oral contraceptive method.

Bimizza® is a combined oral contraceptive or 'birth control' pill that is taken to prevent pregnancy.¹ Each tablet contains 150 micrograms of desogestrel and 20 micrograms of ethinylestradiol.¹

One tablet of Bimizza® should be taken every day until the blister strip is completed, followed by a 7 day pill-free interval before starting the next blister strip of Bimizza® tablets.¹

If you received Mercilon® previously

Bimizza® contains the same active ingredients in the same amounts as Mercilon®, and is therefore considered to work in the same way.¹⁻³

Changing to Bimizza® is as simple as getting used to the new packaging – you'll take the same number of tablets each month, and request repeat prescriptions in the same way as when you took Mercilon®.^{1,2} When taken correctly, Bimizza® is just as effective at preventing pregnancy as Mercilon®.³

Things to remember when taking Bimizza®

Please read the Patient Information Leaflet carefully

You can download a replacement leaflet from <https://www.medicines.org.uk/emc/files/pil.9567.pdf> if you lose or misplace the leaflet that was provided in the box with your Bimizza® tablets.

Request your repeat prescription before you run out of tablets

Please ensure that you contact your GP surgery before you finish the last blister strip provided in your Bimizza® box (i.e. prior to the pill-free interval). This is important as you may need to allow time to schedule a check-up with a healthcare professional before you are given a repeat prescription.

If you want to ask any questions about the information contained in your Patient Information Leaflet or if you have any concerns, please speak to your doctor or other healthcare provider for advice and guidance.

Mercilon® is a registered trademark of Organon Pharma (UK) Ltd.

Bimizza® is marketed in the UK by Morningside Healthcare Limited, Unit C, Harcourt Way, Leicester, LE19 1WP, UK.

References: 1. Morningside Healthcare Ltd. Bimizza 150 microgram/20 microgram Tablets. Summary of Product Characteristics. April 2022. Available at: <https://www.medicines.org.uk/emc/product/9567> (accessed August 2022); 2. Organon Pharma (UK) Ltd. Mercilon Tablets. Summary of Product Characteristics. April 2022. Available at: <https://www.medicines.org.uk/emc/product/1360> (accessed August 2022); 3. MHRA. UK PAR Bimizza 150 microgram/20 microgram tablets. February 2015. Available at: <https://mhraproductsproduction.blob.core.windows.net/docs/33446c8282edba466bfd797be04735e72eb54bca> (accessed August 2022).
Patient Prescription Advisory Leaflet: Patients should always speak to their healthcare provider with any medical enquiries or concerns.

Reporting of side effects

If you get any side effects, talk to your doctor or healthcare provider. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help to provide more information on the safety of this medicine. Adverse events should also be reported to Morningside Healthcare Ltd.'s Medical Information Department on Tel: 0116 478 0322